AbbVie Reports Phase 3 subgroup analysis Data for Elotuzumab in IgG4-related disease

AbbVie today announced Phase 3 subgroup analysis results for Elotuzumab in patients with IgG4-related disease. The study demonstrated that Elotuzumab demonstrates sustained long-term efficacy compared to standard of care or placebo. These results provide important insights into the treatment of IgG4-related disease and support the continued development of Elotuzumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Elotuzumab was consistent with previous observations, with no new safety signals identified.